The Immunology Podcast cover image

Ep. 42: “Immune Mechanisms After Stroke” Featuring Dr. Arthur Liesz

The Immunology Podcast

00:00

The First Patient Trial for T Cells

In the higher dose levels, they had up to four billion T cells being infused. And here's where kind of the, the,. the, the bummer comes in which they did not see very much clinical benefit in any of the 16 patients. In many of them, they could actually find the T cells, the transgenic T cells in their tumors, infiltrating their tumors. But this didn't seem to be sufficient to mediate tumor, uh, reduction. Michael Tubin: I think that's a good proof of principle.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app